[Cancer peptide vaccine therapy based on human genomics approach].
We established a strategy as follows to identify oncoantigens and HLA-restricted epitope peptides, which can be applied as cancer vaccine therapy; i) To identify genes overexpressed in solid tumors using the cDNA microarray, ii) To validate the clinicopathological significance of their protein expression by tissue microarray covering thousands of human cancers, iii) To verify whether they are essential for the cell growth by siRNAs, iv) To screen for the epitope peptides recognized by human HLA-A* 0201/A* 2402-restricted cytotoxic T lymphocyte by ELISPOT assay. We identified dozens of epitopes derived from oncoantigens. In clinical trials, the cancer vaccine therapy against lung cancer using a combination of peptides demonstrated safety and good immunogenicity, and warrants further studies.